Metabolic
AOD-9604
AOD-9604 is a synthetic fragment of human growth hormone (amino acids 177–191, with an N-terminal tyrosine) that targets fat metabolism without causing muscle growth or disrupting insulin. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis via beta-3 adrenergic receptors, without elevating IGF-1. In trials, obese participants lost ~5.7 lb over 12 weeks with diet and exercise; the Phase IIb obesity result was only ~2% vs placebo, so it's best understood as a "fat mobilizer" / fine-tuning tool for already-lean individuals, not a primary appetite suppressant like GLP-1s. Dosed 300 mcg SubQ daily (range 250–500 mcg).
Mechanism
Lipolysis signaling via GH fragment
Clinical Benefits
Fat mobilization, Gentle cut support, No hyperglycemia
Typical Dose
Cycle Length
Frequency
Synergistic Compounds
250-500 mcg
6-12 weeks
Daily (AM fasted)
MOTS-c, L-Carnitine, Reta, Tesamorelin
At a Glance
Dosage | 300 mcg subcutaneous daily (range 250–500 mcg). |
Protocol | 12–16 weeks on, 4 weeks off. Morning fasted, 30–60 min before activity to ensure mobilized fat gets oxidized. |
Results timeline | If no measurable change by week 4, the problem is elsewhere — a marginal optimizer for already-lean individuals, not a primary fat-loss driver. |
Side effects | Indistinguishable from placebo across six RCTs — no IGF-1 elevation, no glucose disruption, no antibody formation. |
Regulatory status | Phase IIb failed for obesity (~2% vs placebo); discontinued 2007. Not FDA-approved (has FDA GRAS food-ingredient status). WADA prohibited. |
Best stacked with | Tesamorelin (anabolic protection during cuts); MOTS-c, L-Carnitine (Morning Partition Stack). |
AOD-9604 failed Phase 3 trials in 2007 — dropped by Metabolic Pharmaceuticals after a ~2% effect vs placebo in severely obese patients. The failure was real, but the logic behind continued niche use holds: a drug that doesn't move the needle for morbid obesity can still matter for someone already lean chasing the last 2–3%. It is the lipolytic fragment of HGH, separated from the growth-promoting region — activating beta-3 receptors in fat tissue without elevating IGF-1, disrupting glucose, or causing edema. That specificity is also its ceiling: a layer-five fine-tuning tool, after diet, training, sleep, and a primary compound are dialed in.
What Is AOD-9604?
A synthetic peptide of HGH amino acids 177–191 (C-terminal region) plus an N-terminal tyrosine for stability. "AOD" = Advanced Obesity Drug; "9604" was its Metabolic Pharmaceuticals development code (Australia, 1990s). The tyrosine modification prevents residual HGH-like effects on IGF-1 or growth — so it isolates the fat-mobilization signal without the hormonal complexity.
How AOD-9604 Works: The Beta-3 Receptor Story
AOD-9604 binds fat cells and upregulates beta-3 adrenergic receptors, making them more responsive to catecholamines (epinephrine/norepinephrine). This increases hormone-sensitive lipase activity, releasing stored triglycerides as free fatty acids.
Knockout study: a 2001 Heffernan mouse study showed normal obese mice had significant fat reduction while beta-3-receptor knockout mice showed no response — proving the effect is entirely beta-3-dependent. Human beta-3 expression varies, which may explain variable responses.
Mobilization ≠ oxidation: released fatty acids must be burned, or they re-esterify and return to storage. AOD-9604 opens the door; activity burns what comes out — which is why timing with activity matters.
The Phase IIb Reality
The OPTIONS trial (534 obese adults, 24 weeks) produced ~2% body-weight reduction vs placebo — below the FDA threshold for an obesity drug — and development was discontinued in 2007. For context, modern GLP-1s deliver ~15% (semaglutide), ~21% (tirzepatide), ~24% (retatrutide in trials). But a failed obesity drug isn't a useless compound: for someone at 12% body fat seeking 10%, a small lipolytic bias layered onto optimized training, nutrition, GLP-1, tesamorelin, and activity may provide the final push.
Exceptional safety: across six randomized double-blind placebo-controlled trials (Stier et al.):
Safety parameter | Result |
IGF-1 elevation | None detected |
Glucose metabolism (OGTT) | No negative effect |
Anti-AOD9604 antibodies | None detected |
Overall tolerability | Indistinguishable from placebo |
Who Should Consider AOD-9604
Good candidates: already lean (sub-15% men / sub-22% women); training 3–4×/week; nutrition dialed; higher-leverage tools optimized; willing to pair with activity; realistic (2–3%) expectations. Not good candidates: obese/overweight (use GLP-1s); expecting dramatic results; skipping fundamentals; unwilling to pair with tesamorelin; seeking a primary tool; competitive athletes (WADA-prohibited).
Layer | Intervention | Effect size |
1 | Nutrition (deficit) | Massive |
2 | Training | Large |
3 | GLP-1 agonists | Large |
4 | Tesamorelin | Moderate |
5 | AOD-9604 | Small |
Dosing Protocol
Dose | 300 mcg daily (range 250–500 mcg) |
Timing | AM fasted, 30–60 min before activity |
Route | Subcutaneous (abdomen preferred, rotate quadrants) |
Cycle | 12–16 weeks on, 4 weeks off |
Evaluation | If no change by week 4, the problem is elsewhere |
Morning fasted + activity: wake fasted → inject 300 mcg SubQ → wait 30–60 min → Zone-2 cardio/training → mobilized fatty acids get burned rather than re-stored. Reconstitute with bacteriostatic water, refrigerate, use within 4–6 weeks; see the reconstitution guide. Inject into abdominal fat (rotate quadrants, 2+ inches from navel); 29–31 gauge insulin syringe.
Stacking Protocols
Morning Partition Stack (fasted): AOD-9604 300 mcg SC (mobilizes fat), L-Carnitine 500 mg IM (shuttles fat into mitochondria), MOTS-c 5–10 mg SC (programs mitochondria to prefer fat) → then 30–60 min Zone-2 cardio. Complete cutting protocol: add evening Tesamorelin 1–2 mg SC (anabolic protection), weekly GLP-1 agonist, resistance training 3–4×/week, protein 1.6–2.2 g/kg. Tesamorelin is required because AOD provides zero muscle protection.
AOD-9604 vs Tesamorelin
Property | AOD-9604 | Tesamorelin |
What it is | HGH fragment 177-191 (lipolytic domain) | Full GHRH(1-44) analog |
Mechanism | Beta-3 receptor activation on fat cells | Restores pulsatile GH secretion |
IGF-1 effect | None | Elevates (requires monitoring) |
Muscle protection | None | Yes — nitrogen retention |
Fat targeting | General lipolysis (needs activity) | Visceral fat (15–20% VAT reduction) |
Clinical evidence | Phase IIb failed (~2% vs placebo) | FDA-approved; multiple positive RCTs |
Role | Optional fine-tuning (layer 5) | Core anabolic protection (layer 4) |
If you can only choose one, choose tesamorelin. Running both: tesamorelin at night, AOD in the morning.
Side Effects and Safety
Occasional injection-site reactions and headache; rare nausea/GI upset. Notably does NOT cause IGF-1 elevation, glucose disruption, edema, carpal tunnel, antibody formation, or pituitary suppression. Received FDA GRAS (Generally Recognized As Safe) status as a food ingredient in 2019 — not therapeutic approval, but a reinforcing safety signal. WADA-prohibited under S2 (Peptide Hormones, Growth Factors) due to its HGH-fragment origin.
FAQ
Does AOD-9604 actually work?
Mechanistically yes (beta-3 activation, lipolysis); clinically the effect is modest (~2% in trials). For already-lean individuals with fundamentals optimized, the marginal lipolytic bias may help stubborn areas. For significant fat loss, GLP-1 agonists are far more effective.
What is the recommended dosage and protocol?
300 mcg SubQ daily in the abdomen, morning fasted, 30–60 min before activity (range 250–500 mcg; higher isn't proportionally better). Cycles ~8 weeks on, 4 weeks off. Must be paired with activity to oxidize mobilized fat.
Does AOD-9604 need to be cycled?
Typically 8-week courses with 4-week breaks, though cycling is less critical since it doesn't affect IGF-1 or hormonal axes. Breaks are mostly for honest assessment.
How long until I see results?
Subtle effects over 4–8 weeks, not dramatic transformation. Don't expect semaglutide-level changes.
What are the side effects?
Occasional injection-site reactions and headaches, rare nausea. Does NOT elevate IGF-1, disrupt glucose, cause edema, or cause carpal tunnel — one of the safest peptides available.
Can I take AOD-9604 with GLP-1 medications?
Yes — entirely different mechanisms (beta-3 vs GIP/GLP-1), no interaction. GLP-1 does the heavy lifting; AOD adds a marginal lipolytic signal for stubborn areas. GLP-1 weekly, AOD daily AM fasted.
How do I store AOD-9604?
Powder: refrigerate or freeze. Reconstituted: refrigerate (2–8°C), use within 4–6 weeks; protect from light/temperature swings.
Is AOD-9604 the same as HGH fragment?
It's the 177–191 lipolytic fragment of HGH, modified with a tyrosine to prevent IGF-1/growth effects — derived from HGH but engineered to isolate only fat mobilization.
Is AOD-9604 banned in sports?
Yes — WADA prohibits it under peptide hormones/growth factors due to its HGH-fragment origin, despite minimal performance enhancement.
Why pair AOD-9604 with tesamorelin?
AOD provides zero muscle protection; tesamorelin restores GH pulsatility for anabolic support. Using AOD alone during a deficit risks disproportionate lean-mass loss.
Related Topics
Tesamorelin Guide — GH-axis support with muscle preservation
Semaglutide Guide — primary fat-loss tool
Tirzepatide Guide — better body-composition data
MOTS-c Guide — mitochondrial support for the morning stack
L-Carnitine — fatty-acid transport in the morning stack
Reconstitution Guide — peptide preparation
Retatrutide Guide — triple-agonist; AOD-9604 as an adjunct for stubborn areas
References
Heffernan M, Summers RJ, Thorburn A, et al. Effects of HGH and its lipolytic fragment (AOD9604) on lipid metabolism — beta-3-AR knockout. Endocrinology 2001;142(12):5182-5189. PMID 11713213. DOI
Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab 2013;3(1-2):7-15. DOI
Ng FM, Sun J, Sharma L, et al. Metabolic effects of AOD9604 on obese Zucker rats. J Mol Endocrinol 2000;25(3):287-294. PMID 11146367. DOI
Cox HD, Rampton J, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal 2015;7(1):31-38. PMID 25208511. DOI
Valentino MA, Lin JE, Snook AE, et al. Central and peripheral molecular targets for anti-obesity pharmacotherapy. Clin Pharmacol Ther 2010;87(6):652-662. DOI
Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs 2004;5(4):431-437. PMID 15134286.
AOD9604 overview. Wikipedia
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.